BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00017043
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-08-28
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00067782
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
- First Posted Date
- 2003-07-29
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 195
- Registration Number
- NCT00065507
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇬🇷Local institution, Athens, Greece
🇺🇸Mount Sinai Medical Center, New York, New York, United States
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
- First Posted Date
- 2003-04-03
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00057473
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00024284
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
- Conditions
- Hepatitis B
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00051038
- Locations
- 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2002-12-17
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00050596
- Locations
- 🇺🇸
University Urological Research Institute, Providence, Rhode Island, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸San Diego Uro-Research, San Diego, California, United States
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2002-11-22
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00050102
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Cancer Institute Medical Group, Santa Monica, California, United States
🇺🇸Indiana Oncology/ Hematology Consultants, Indianapolis, Indiana, United States
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1250
- Registration Number
- NCT00048568
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1795
- Registration Number
- NCT00048932
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States